Antioxidant, B vitamin combo to slow dementia?

- Last updated on GMT

Related tags: Vitamin, Folic acid, Alzheimer's disease

Combining B vitamins with a powerful antioxidant could lower blood
levels of the amino acid homocysteine enough to prevent dementia,
claims a UK research firm preparing to test the theory in clinical
trials.

High blood levels of homocysteine are a known risk factor for stroke and dementia but although homocysteine can be lowered by standard B vitamin supplements it is not yet known whether these can be used to treat or prevent dementia.

So far, the small studies on this effect have been disappointing.

However homocysteine research company Cobalz​ says that clinical trials starting in January could confirm that adding B vitamins to the powerful antioxidant N-acetylcysteine is superior to standard B vitamins in slowing the rate of cognitive decline in Alzheimer's disease patients.

Dementia already affects millions around the world and the threat is increasing with the growing numbers of elderly. Alzheimer's disease, the leading cause of dementia in the elderly, afflicts an estimated 4.5 million people in the US alone.

The condition is not only associated with homocysteine levels but also with 'free radicals' that oxidise and damage an enzyme that breaks down homocysteine.

Cobalz has found that adding a powerful antioxidant to B vitamins lowers homocysteine levels even further and results in prompt, striking and sustained clinical improvement in patients.

Cobalz claims that the glutathione precursor N-acetylcysteine (NAC)is not only a potent antioxidant but also a source of cysteine. Cysteine is required to generate hydrogen sulphide - an important neuromodulator and vasorelaxant. Levels of hydrogen sulphide levels are severely decreased in the brains of Alzheimer's disease patients.

Last week the firm signed a licensing agreement with US pharmaceutical firm Pamlab to produce the product scheduled for use in the trial by researchers at the University of Texas Southwestern Medical Center.

Neil McCaddon, global head of licensing and corporate development at Cobalz, said: "We are very excited about the possibilities, and hope to announce some real breakthroughs for sufferers of dementia, and their carers."

The UK company is seeking other licensing and development partners for the rest of the global market.

Related topics: Research, Suppliers, Cognitive function

Related news

Show more

Related products

show more

Omegavie® DHA algae Capsules

Omegavie® DHA algae Capsules

POLARIS | 23-Aug-2018 | Application Note

Omegavie® DHA algae capsules is a real opportunity to consume high-performing Omega-3 DHA 100% vegan, natural, sustainable, GMO- and allergen-free. Designed...

Adulteration: Don’t Be Fooled, Know the Facts

Adulteration: Don’t Be Fooled, Know the Facts

SABINSA: our innovation is your answer® | 09-Jul-2018 | Technical / White Paper

Increased knowledge and awareness of natural products has in turn increased their global demand. This well documented paper highlights various examples,...

Learn how Neumentix™ works for active consumers

Learn how Neumentix™ works for active consumers

Kemin Human Nutrition & Health | 22-May-2018 | Technical / White Paper

New clinical trial data revealed Neumentix improved young recreationally active participants’ cognitive and physical performance after 30 days of supplementation...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars